Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment With Inavolisib Combinations in Patients With Untreated, Early-stage, PIK3CA-Mutated Breast Cancer

NCT07054190 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT07054190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07054190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment With Inavolisib Combinations in Patients With Untreated, Early-stage, PIK3CA-Mutated Breast Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Recruiting
Start date
September 9, 2025
Completion date
September 28, 2027
Enrollment
120 (estimated)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer